###begin article-title 0
Interplay in the Selection of Fluoroquinolone Resistance and Bacterial Fitness
###end article-title 0
###begin p 1
Conceived and designed the experiments: DH. Performed the experiments: LLM NFM DH. Analyzed the data: LLM DH. Contributed reagents/materials/analysis tools: NFM. Wrote the paper: DH.
###end p 1
###begin p 2
###xml 251 258 251 258 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E. coli</italic>
###xml 735 743 735 743 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 748 755 748 755 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 884 892 884 892 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 897 904 897 904 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 1024 1028 1024 1028 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">parC</italic>
###xml 1114 1118 1114 1118 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">gyrA</italic>
###xml 1136 1140 1136 1140 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">marR</italic>
###xml 1241 1245 1241 1245 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">gyrA</italic>
###xml 1379 1383 1379 1383 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">parC</italic>
###xml 251 258 <span type="species:ncbi:562">E. coli</span>
Fluoroquinolones are antibacterial drugs that inhibit DNA Gyrase and Topoisomerase IV. These essential enzymes facilitate chromosome replication and RNA transcription by regulating chromosome supercoiling. High-level resistance to fluoroquinolones in E. coli requires the accumulation of multiple mutations, including those that alter target genes and genes regulating drug efflux. Previous studies have shown some drug-resistance mutations reduce bacterial fitness, leading to the selection of fitness-compensatory mutations. The impact of fluoroquinolone-resistance on bacterial fitness was analyzed in constructed isogenic strains carrying up to 5 resistance mutations. Some mutations significantly decreased bacterial fitness both in vitro and in vivo. We identified low-fitness triple-mutants where the acquisition of a fourth resistance mutation significantly increased fitness in vitro and in vivo while at the same time dramatically decreasing drug susceptibility. The largest effect occurred with the addition of a parC mutation (Topoisomerase IV) to a low-fitness strain carrying resistance mutations in gyrA (DNA Gyrase) and marR (drug efflux regulation). Increased fitness was accompanied by a significant change in the level of gyrA promoter activity as measured in an assay of DNA supercoiling. In selection and competition experiments made in the absence of drug, parC mutants that improved fitness and reduced susceptibility were selected. These data suggest that natural selection for improved growth in bacteria with low-level resistance to fluoroquinolones could in some cases select for further reductions in drug susceptibility. Thus, increased resistance to fluoroquinolones could be selected even in the absence of further exposure to the drug.
###end p 2
###begin title 3
Author Summary
###end title 3
###begin p 4
###xml 28 33 <span type="species:ncbi:9606">human</span>
The increasing frequency of human pathogens resistant to important classes of antibiotics poses a serious and growing challenge for medicine and society. We need improved strategies to reduce the rate of resistance development, for established and novel drugs, based on knowledge of the factors that drive the increase in resistance. Resistance to fluoroquinolones in most bacteria develops via a series of sequential genetic changes affecting several different genes. These are selected and enriched in bacterial populations by exposure to the drug. Relevant factors driving this increase include overuse, and inappropriate use, of these drugs. In this paper we show that mutant bacteria with low-level resistance (not itself a problem to treat with standard drug doses) can evolve by natural selection (for improved growth rate) to acquire mutations that dramatically increase their level of drug resistance. This means that we may need to consider how to reduce inappropriate drug use that can enrich for bacteria with low-levels of resistance, because at that stage some of the mutant bacteria in the population may continue to evolve higher level resistance even in the absence of any further drug exposure.
###end p 4
###begin title 5
Introduction
###end title 5
###begin p 6
###xml 48 51 48 51 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000541-Andriole1">[1]</xref>
###xml 239 242 239 242 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000541-Hooper1">[2]</xref>
###xml 316 323 316 323 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E. coli</italic>
###xml 435 438 435 438 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000541-EARSS1">[3]</xref>
###xml 525 532 525 532 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E. coli</italic>
###xml 641 644 641 644 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000541-KompLindgren1">[4]</xref>
###xml 705 713 705 713 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 718 725 718 725 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 725 728 725 728 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000541-KompLindgren2">[5]</xref>
###xml 729 732 729 732 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000541-Andersson2">[7]</xref>
###xml 853 856 853 856 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000541-Gould1">[8]</xref>
###xml 944 947 944 947 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000541-Ferech1">[9]</xref>
###xml 984 991 984 991 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E. coli</italic>
###xml 1058 1061 1046 1049 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000541-EARSS1">[3]</xref>
###xml 1134 1137 1122 1125 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000541-Ferech1">[9]</xref>
###xml 316 323 <span type="species:ncbi:562">E. coli</span>
###xml 525 532 <span type="species:ncbi:562">E. coli</span>
###xml 984 991 <span type="species:ncbi:562">E. coli</span>
Fluoroquinolones are potent antibacterial drugs [1] that bind to bacterial type II topoisomerases (DNA gyrase and topoisomerase IV) when they are in complex with DNA. The drugs inhibit chromosome re-ligation after enzyme-mediated cleavage [2]. Fluoroquinolones are effective against many bacteria including invasive E. coli, but resistance is increasing with 28 of 29 countries in Europe reporting a significant rise between 2001-2007 [3]. The rapid increase is surprising because clinically relevant levels of resistance in E. coli require multiple genetic changes, including mutations altering topoisomerases and up-regulating drug efflux [4], changes that are associated with reduced bacterial fitness in vitro and in vivo[5]-[7]. Inappropriate use of fluoroquinolones, or co-selection of resistant bacteria with the use of other antimicrobial drugs [8] may be factors driving the increase in resistance but these may not be the sole causes [9]. For example, resistant isolates of E. coli increased from approximately7-19% between 2001 and 2007 in the UK [3], while outpatient fluoroquinolone use remained unchanged from 1997-2003 [9]. To develop an effective strategy to restrict the increase in resistance frequency will require that we have a full understanding of the factors driving the increase. The aim of this paper was to investigate whether selection for improved fitness in bacteria might itself be a factor promoting increased resistance.
###end p 6
###begin p 7
###xml 239 246 239 246 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E. coli</italic>
###xml 398 401 398 401 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000541-KompLindgren2">[5]</xref>
###xml 538 541 538 541 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000541-KompLindgren2">[5]</xref>
###xml 603 627 603 627 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Streptococcus pneumoniae</italic>
###xml 669 673 669 673 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000541-Rozen1">[10]</xref>
###xml 976 983 976 983 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 1168 1175 1168 1175 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E. coli</italic>
###xml 239 246 <span type="species:ncbi:562">E. coli</span>
###xml 603 627 <span type="species:ncbi:1313">Streptococcus pneumoniae</span>
###xml 1168 1175 <span type="species:ncbi:562">E. coli</span>
The fitness costs of drug resistance can be reduced by selection of low-cost mutations or by the accumulation of secondary fitness-compensating mutations that do not reduce resistance. During experimental evolution of clinical isolates of E. coli for decreased susceptibility to fluoroquinolones most lineages (16/18) suffered reduced growth competitiveness after only two or three selection steps [5]. However, lineages selected for further decreases in susceptibility were occasionally associated with a relative restoration of fitness [5]. A similar reversal was noted in some constructed strains of Streptococcus pneumoniae carrying one or two resistance mutations [10]. These data suggested that some resistance mutations might be selected because they decrease susceptibility to the drug and simultaneously reduce the fitness costs associated with existing resistance mutations. No cause for the phenomenon has been demonstrated, and it's relevance to bacterial fitness in vivo in not clear. To examine the phenomenon we constructed isogenic strains carrying various combinations of five resistance mutations found commonly in fluoroquinolone-resistant clinical E. coli, and measured their drug-susceptibility and fitness. The relationships between the number of resistance mutations and bacterial fitness were complex and the addition of a resistance mutation was shown in some cases to improve bacterial fitness. These findings have implications for the evolution of fluoroquinolone resistance in the absence of antibiotic exposure.
###end p 7
###begin title 8
Results
###end title 8
###begin title 9
Resistance and fitness in clinical isolates: the paradox
###end title 9
###begin p 10
###xml 4 11 4 11 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E. coli</italic>
###xml 50 53 50 53 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000541-KompLindgren1">[4]</xref>
###xml 192 196 186 190 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">gyrA</italic>
###xml 223 227 213 217 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">parC</italic>
###xml 273 278 261 266 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">marOR</italic>
###xml 324 328 312 316 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">acrR</italic>
###xml 413 416 401 404 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000541-KompLindgren1">[4]</xref>
###xml 596 600 584 588 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000541-Gagneux1">[11]</xref>
###xml 601 605 589 593 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000541-ONeill1">[12]</xref>
###xml 672 675 660 663 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000541-Andersson2">[7]</xref>
###xml 1059 1066 1047 1054 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="ppat-1000541-t001">Table 1</xref>
###xml 1118 1122 1106 1110 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">gyrA</italic>
###xml 1124 1128 1112 1116 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">parC</italic>
###xml 1180 1184 1159 1163 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">marR</italic>
###xml 1191 1195 1166 1170 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">acrR</italic>
###xml 1264 1268 1239 1243 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">gyrA</italic>
###xml 1273 1277 1248 1252 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">parC</italic>
###xml 1394 1415 1364 1385 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s4">Materials and Methods</xref>
###xml 1636 1640 1606 1610 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">gyrA</italic>
###xml 1645 1649 1615 1619 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">parC</italic>
###xml 4 11 <span type="species:ncbi:562">E. coli</span>
###xml 579 586 <span type="species:ncbi:9606">patient</span>
The E. coli urinary tract infection isolate C1186 [4] is highly-resistant to fluoroquinolones (MIC for ciprofloxacin >/=32 microg/ml) and carries resistance mutations altering topoisomerases (gyrA Ser83-->Leu, Asp87-->Asn; parC Ser80-->Ile), and up-regulating drug efflux (marOR small deletion, and amino acid substitution; acrR IS1 insertion). These 5 mutations are typical of highly resistant clinical isolates [4]. C1186 has a growth rate similar to a laboratory wild-type. Thus, these resistance mutations may individually be low-cost, as found for some rifampicin-resistant patient isolates [11],[12] or the strain may carry additional fitness-compensatory mutations [7]. A third possibility is that some resistance mutations reduce existing fitness costs while simultaneously decreasing susceptibility to the drug. This last possibility is highly relevant to the multi-step nature of fluoroquinolone-resistance development. We constructed 28 isogenic derivatives of the wild-type MG1655, each mimicking in part the complex resistance genotype of C1186 (Table 1). Mutations were initially isolated spontaneously (gyrA, parC) or constructed by lambda-red recombineering (DeltamarR, DeltaacrR) and then separately introduced into MG1655 by P1 transduction. The gyrA and parC mutations were transduced by selection for a linked genetic marker (introduced using lambda-red recombineering, see Materials and Methods) and at least 20 transductants of each cross were subsequently screened by phenotype (MIC) and DNA sequencing for the linked mutation. In every case only two phenotypic and genotypic classes were found, showing that the gyrA and parC mutations were not associated with other mutations.
###end p 10
###begin title 11
Genotypes, susceptibility, and fitness of isogenic strains.
###end title 11
###begin p 12
Genotype. Strains are isogenic to MG1655 and carry only the mutations shown.
###end p 12
###begin p 13
MIC for ciprofloxacin (microg/ml).
###end p 13
###begin p 14
###xml 176 181 172 177 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">araBC</italic>
Fitness. Mean fitness per generation, relative to wild-type, SD, standard deviation (within parentheses) measured in pair wise competition against the isogenic wild-type (DeltaaraBC).
###end p 14
###begin p 15
P. Statistical significance of difference in fitness relative to the wild-type (Students t-test (95% confidence limit, two-tailed P-value).
###end p 15
###begin p 16
N. Number of independent competition experiments on which the fitness value is based.
###end p 16
###begin title 17
Susceptibility of isogenic mutant strains
###end title 17
###begin p 18
###xml 52 59 52 59 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="ppat-1000541-t001">Table 1</xref>
###xml 208 212 206 210 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">gyrA</italic>
###xml 299 303 297 301 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">marR</italic>
###xml 308 312 306 310 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">acrR</italic>
###xml 373 377 371 375 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">parC</italic>
###xml 502 506 496 500 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">marR</italic>
###xml 512 516 502 506 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">acrR</italic>
###xml 573 577 563 567 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">parC</italic>
###xml 605 617 595 607 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E. coli parC</italic>
###xml 686 690 676 680 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">gyrA</italic>
###xml 948 952 934 938 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000541-EUCAST1">[13]</xref>
###xml 1145 1153 1131 1139 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000541-g001">Figure 1</xref>
###xml 605 612 <span type="species:ncbi:562">E. coli</span>
MIC for ciprofloxacin was measured for each strain (Table 1). The margin of error of MIC values is +/-1 half-doubling step. Accordingly, any change that is at least 2-fold is significant. Single mutations in gyrA, S83L and D87N, increased MIC 24-fold and 16-fold respectively. Knockout mutations in marR and acrR increased MIC only 2-3-fold, while the substitution S80I in parC had no effect on MIC. Double mutation combinations had MIC's that were 8-64-fold wild-type level, with the combination DeltamarR+DeltaacrR having the smallest increase. Certain combinations with parC were not tested because in E. coli parC mutations only selected after the prior occurrence of a mutation in gyrA. Triple mutation combinations have MIC's that were 31-2000-fold wild-type level. Most strains with three resistance mutations (5/9), and all strains with 4 or 5 mutations had MIC's above the 1 microg/ml breakpoint that defines clinical resistance in Europe [13] equivalent to 64-fold wild-type MIC in these strains. On average there was a positive correlation between the number of resistance mutations carried by a strain and the MIC for ciprofloxacin (Figure 1).
###end p 18
###begin title 19
Resistance and fitness of constructed strains.
###end title 19
###begin p 20
###xml 144 152 144 152 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 438 445 438 445 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="ppat-1000541-t002">Table 2</xref>
For the wild-type and each of the 28 constructed isogenic strains the MIC for ciprofloxacin (part A) and the relative fitness per generation in in vitro growth competition (part B) is shown as a function of the number of resistance mutations per strain. Each diamond symbol represents one strain. In some cases more than one symbol occupies the same space. Strain identification numbers are shown for four strains of particular interest (Table 2).
###end p 20
###begin title 21
Fitness of isogenic resistant strains
###end title 21
###begin p 22
###xml 111 115 111 115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000541-Demetrius1">[14]</xref>
###xml 116 120 116 120 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000541-Fisher1">[15]</xref>
###xml 177 184 177 184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="ppat-1000541-t001">Table 1</xref>
###xml 346 350 334 338 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">gyrA</italic>
###xml 357 361 345 349 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">gyrA</italic>
###xml 372 376 360 364 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">parC</italic>
###xml 431 435 415 419 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">marR</italic>
###xml 445 449 425 429 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">acrR</italic>
###xml 914 922 880 888 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000541-g001">Figure 1</xref>
###xml 1201 1205 1167 1171 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">marR</italic>
###xml 1210 1214 1176 1180 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">acrR</italic>
The 28 mutant strains were tested in growth competitions against wild-type to measure their Malthusian fitness [14],[15] as a function of the resistance mutations they carried (Table 1). The fitness value associated with having either one or two resistance mutations ranged from approximately1 down to 0.82 per generation. Some single mutations (gyrA S83L, gyrA D87N, and parC S80I) were statistically neutral whereas others (DeltamarR and DeltaacrR) caused a significant reduction in fitness (0.83 and 0.91 per generation, respectively). Strains carrying three resistance mutations had fitness values that ranged from approximately1 down to as low as 0.60, with 8/9 strains suffering a fitness deficit of >/=5% per generation. Interestingly, the addition of a fourth resistance mutation to these strains restricted the minimum fitness value to 0.66 per generation, higher than that measured with three mutations (Figure 1). When all five resistance mutations were present the fitness value was 0.68. Thus, some strains carrying 4 or 5 resistance mutations have a higher fitness than some strains carrying only 3 mutations. The major negative effect on fitness was associated with the presence of the marR and acrR mutations. Thus, fitness did not decrease as a simple function of the number of resistance mutations, but instead depended critically on the nature of those mutations.
###end p 22
###begin title 23
For some strains an increased MIC correlates with improved fitness
###end title 23
###begin p 24
###xml 171 179 171 179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000541-g001">Figure 1</xref>
###xml 181 188 181 188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="ppat-1000541-t001">Table 1</xref>
###xml 351 355 351 355 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">gyrA</italic>
###xml 368 372 368 372 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">parC</italic>
###xml 482 489 482 489 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="ppat-1000541-t001">Table 1</xref>
###xml 1190 1193 1190 1193 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000541-KompLindgren1">[4]</xref>
###xml 1279 1283 1279 1283 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">marR</italic>
###xml 1420 1428 1414 1422 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000541-g001">Figure 1</xref>
###xml 1433 1440 1427 1434 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="ppat-1000541-t001">Table 1</xref>
###xml 1488 1492 1482 1486 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">gyrA</italic>
###xml 1496 1500 1490 1494 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">parC</italic>
###xml 1650 1657 1642 1649 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="ppat-1000541-t002">Table 2</xref>
###xml 1958 1962 1950 1954 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">gyrA</italic>
###xml 1970 1974 1962 1966 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">parC</italic>
###xml 2443 2450 2435 2442 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="ppat-1000541-t002">Table 2</xref>
In general the addition of a resistance mutation to a strain was either neutral with respect to MIC and fitness, or it caused an increased MIC and / or decreased fitness (Figure 1, Table 1). Across all the strains constructed decreased fitness was very strongly associated with the presence of one or both efflux mutations. In contrast, strain LM693 (gyrA S83L, D87N; parC S80I) has high level resistance (MIC 32) with no significant reduction in fitness relative to the wild-type (Table 1). LM693 shows that it is possible to evolve high level resistance with no, or minimal, fitness costs. However, mutations up-regulating drug efflux are highly relevant to resistance evolution because they arise at a rate hundreds of times higher than mutations in the structural genes for topoisomerases. This is because the genetic target for knockout mutations in efflux regulating genes is much larger than the target for the specific amino acid substitutions required in topoisomerase genes. Thus, even though, as shown here, efflux mutations are fitness-costly and contribute relatively small increases in resistance, they occur very frequently, and are found in many resistant clinical isolates [4]. For three low-fitness strains, each carrying three resistance mutations including a marR mutation, the addition of an extra resistance mutation increased both MIC and fitness: LM695-->LM707; LM882-->LM707; and LM871-->LM707 (Figure 1 and Table 1). In these strains the added mutation affected gyrA or parC. The increased fitness was statistically significant (Students t-test, two-tailed, p<0.05) in two of the three cases, LM695>LM707 and LM882-->LM707 (Table 2). The robustness of these results was verified by independently reconstructing each of these strains and re-measuring their MIC and fitness values. No significant differences were found from the original values. In addition, we tested these critical strains by de-construction experiments: replacing gyrA and/or parC mutations with equivalent wild-type genes and determining that the MIC and fitness values of the de-constructed strains were as expected. Based on these two experiments, re-constuction, and de-construction, we are confident that the isogenic strains do not carry any additional mutations affecting MIC or fitness. Thus, the addition of a single resistance mutation can increase growth fitness by 5-10% per generation and simultaneously increase MIC more than 40-fold (Table 2).
###end p 24
###begin title 25
Single mutations decrease drug susceptibility and increase fitness.
###end title 25
###begin p 26
Genotype; All strains are isogenic to MG1655 and carry only the mutations shown.
###end p 26
###begin p 27
MIC for ciprofloxacin (microg/ml).
###end p 27
###begin p 28
Fitness; Mean fitness per generation (relative to wild-type). SD, standard deviation (within parentheses) measured in pair wise competition against the isogenic wild-type.
###end p 28
###begin p 29
P; Significance of fitness difference between the strains in each pair, (Students t-test, two-tailed P-value).
###end p 29
###begin p 30
N; Number of independent competition experiments on which the fitness value is based.
###end p 30
###begin title 31
###xml 13 18 <span type="species:ncbi:10090">mouse</span>
Fitness in a mouse infection model
###end title 31
###begin p 32
###xml 180 188 180 188 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 313 321 313 321 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 412 416 412 416 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000541-Hvidberg1">[16]</xref>
###xml 791 798 791 798 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 803 811 803 811 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 813 821 813 821 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000541-g002">Figure 2</xref>
###xml 904 912 904 912 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 964 971 964 971 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 386 391 <span type="species:ncbi:10090">mouse</span>
###xml 515 520 <span type="species:ncbi:10090">mouse</span>
The data in the previous section showed that the addition of a fourth resistance mutation to either LM695 or LM882 could significantly increase competitive growth fitness measured in vitro. This result would be more interesting from a clinical viewpoint if the measured increase in fitness was not exclusively an in vitro phenomenon. To test this competition experiments were made in a mouse UTI infection model [16]. Each of the strains (LM695, LM883, and LM707) was competed against the isogenic wild-type in the mouse model and relative fitness expressed as a competitive index (C.I.).Three different measures of C.I. could be obtained in this model: from the urine; the bladder; and the kidneys. For each strain and tissue there was a clear positive correlation between relative fitness in vivo and in vitro (Figure 2). Thus, the relative order of fitness values of these strains, initially measured in vitro, was confirmed in the physiologically more complex in vivo environments.
###end p 32
###begin title 33
###xml 8 16 8 16 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 42 49 42 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 55 60 <span type="species:ncbi:10090">mouse</span>
Fitness in vitro as a function of fitness in vivo in a mouse UTI model.
###end title 33
###begin p 34
###xml 225 233 225 233 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 238 245 238 245 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
Samples from urine, kidney, and bladder are illustrated with black diamonds, triangles, and squares, respectively. The addition of one extra resistance mutation to either LM695, or LM882 created LM707, with increased fitness in vitro and in vivo and an increase in MIC for ciprofloxacin from 0.75 to 32 microg/ml.
###end p 34
###begin title 35
Fitness compensation and changes in DNA supercoiling
###end title 35
###begin p 36
###xml 4 8 4 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">marR</italic>
###xml 96 103 96 103 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="ppat-1000541-t001">Table 1</xref>
###xml 110 114 110 114 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">marR</italic>
###xml 217 221 215 219 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">marR</italic>
###xml 318 322 316 320 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000541-Grkovic1">[17]</xref>
###xml 398 401 396 399 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">mar</italic>
###xml 730 733 728 731 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">mar</italic>
###xml 1043 1047 1039 1043 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000541-Clark1">[18]</xref>
###xml 1227 1231 1223 1227 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000541-Bagel1">[19]</xref>
###xml 1232 1236 1228 1232 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000541-Preisler1">[20]</xref>
###xml 1355 1359 1351 1355 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">topA</italic>
###xml 1365 1369 1361 1365 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">gyrA</italic>
###xml 1462 1466 1458 1462 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000541-Preisler1">[20]</xref>
###xml 1494 1498 1490 1494 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">topA</italic>
###xml 1502 1506 1498 1502 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">gyrA</italic>
###xml 1689 1693 1685 1689 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000541-Bagel1">[19]</xref>
###xml 1694 1698 1690 1694 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000541-Preisler1">[20]</xref>
###xml 2158 2162 2154 2158 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">gyrA</italic>
###xml 2239 2243 2235 2239 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">parC</italic>
###xml 2793 2797 2789 2793 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">gyrA</italic>
###xml 2920 2924 2916 2920 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">gyrA</italic>
The marR mutation makes the single largest contribution to loss of fitness in these 28 strains (Table 1). The marR mutation alone reduced fitness to 0.83+/-0.3 (LM202), and the average fitness of all strains carrying marR is 0.76 (SD 0.08). MarR protein regulates, directly and indirectly, transcription of many genes [17] and the reduction in fitness associated with loss of function mutations in mar is most likely because of disruption of gene regulation. This suggests a possible mechanism of fitness compensation associated with resistance mutations in topoisomerase genes. Thus, some topoisomerase mutations that alter chromosomal supercoiling levels may partially restore expression of growth-limiting gene(s) regulated by mar, reversing the fitness deficit. This hypothesis predicts that the improvement in fitness measured in LM695-->LM707 should be associated with a change in global supercoiling level. This was tested by electrophoresis of pUC18 and pUC19 plasmids purified from MG1655, LM695 and LM707 in chloroquine-agarose gels [18]. With this method we were unable to detect differences in plasmid topoisomer patterns (data not shown). We also tested for differences in supercoiling using a reporter gene assay [19],[20]. This was done by introducing plasmids carrying a luciferase reporter gene fused to each of two different promoters (ptopA and pgyrA) whose expression is sensitive to, respectively, increased or decreased supercoiling levels [20]. In this assay the ratio (ptopA / pgyrA) of reporter gene expression from these two promoters, defined as the quotient of supercoiling (Qsc), is a measure of the relative level of negative supercoiling in isogenic strains [19],[20]. Qsc was 2.9 (SD 0.7) for MG1655 (n = 6), 2.6 (SD 0.7) for LM695 (n = 12), and 3.6 (SD 1) for LM707 (n = 13). In this assay neither of the mutant strains differed significantly from the wild-type, but LM695 and LM707 differed significantly from each other (P value 0.01, Students t-test, two tailed). From the expression data it was clear that the major cause of this difference in Qsc between LM695 and LM707 was due to a 25% decrease in expression from the gyrA promoter construct in LM707 relative to LM695. Thus the introduction of the parC S80I mutation to make strain LM707 caused a significant increase in the Qsc, coincident with the improvement in fitness. Although we cannot explain the absence of an effect in the chloroquine-agarose assay, the reporter gene assay suggests that some changes in chromosomal supercoiling associated with the acquisition of topoisomerase mutations may provide a mechanism linking bacterial fitness and decreased susceptibility to fluoroquinolones. However, an alternative explanation is that the combination of mutations in LM707 reduces expression of gyrA by a mechanism that does not change global supercoiling levels, and that it is a consequence of the reduced expression of gyrA that causes the increase in growth fitness. Additional experiments will be required to distinguish between these models.
###end p 36
###begin title 37
Selection of improved-fitness highly-resistant mutants
###end title 37
###begin p 38
###xml 60 64 60 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">parC</italic>
###xml 574 578 574 578 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">parC</italic>
###xml 963 970 951 958 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="ppat-1000541-t001">Table 1</xref>
###xml 1126 1127 1114 1115 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 1160 1161 1148 1149 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">8</sup>
###xml 1257 1258 1229 1230 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 1607 1609 1571 1573 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;8</sup>
###xml 2274 2276 2234 2236 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;8</sup>
###xml 2353 2354 2313 2314 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 2784 2788 2744 2748 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">gyrA</italic>
###xml 2793 2794 2753 2754 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 2799 2803 2759 2763 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">parC</italic>
###xml 2808 2809 2768 2769 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E</italic>
###xml 2818 2822 2778 2782 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">marR</italic>
###xml 2827 2831 2787 2791 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">acrR</italic>
###xml 2984 2988 2944 2948 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">parC</italic>
###xml 3223 3230 3167 3174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="ppat-1000541-t003">Table 3</xref>
###xml 3270 3274 3214 3218 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">parC</italic>
In the sections above it was shown that the transfer of the parC S80I mutation into LM695 increased its MIC for ciprofloxacin and its competitive growth fitness versus the wild-type. This predicted that the resulting constructed strain, LM707, should outcompete LM695 in a head-to-head competition, and also raised the following questions: (i) could a mutant with an increased MIC for ciprofloxacin and a higher growth fitness be selected spontaneously from LM695 in the absence of drug; and (ii) would such a mutant be exclusively associated with of the acquisition of the parC S80I mutation. These predictions and questions were addressed experimentally. First, in head-to-head growth competition experiments in LB medium with no drug, LM707 (four resistance mutations) outcompeted LM695 (three resistance mutations), gaining approximately8% per generation, in good agreement with the relative differences in growth fitness of each strain versus the wild-type (Table 1). Second, 96 independent lineages of LM695 were grown in rich medium in the absence of drug for 4 growth cycles. Each growth cycle was inoculated with 2x106 cfu and grown to a total of 2x108 cfu (approximately7 generations per growth cycle) in a volume of 200 microL. An aliquot of 5x106 cfu from each lineage was tested, after the completion of 2, 3, and 4 cycles of growth, for the presence of resistant mutants on solid medium (3 microg/mL ciprofloxacin, 4xMIC). Growth of LM695 is completely inhibited on 3 microg/mL ciprofloxacin and the spontaneous mutation rate to resistance on this media, measured in fluctuation tests, is 2x10-8. Accordingly, we expected that virtually none of the 96 independent lineages would contain a resistant mutant at the initiation of the experiment, but that a small number of resistant mutants would arise in each lineage during each growth cycle. If these mutants out-competed the parental LM695 they would be expected to increase relative to LM695, and thus have a greater probability of being transferred to the next growth cycle. The number of lineages from which resistant mutants were obtained was found to increase with successive growth cycles: from 2/96 (cycle 2)-->8/96 (cycle 3)-->15/96 (cycle 4). Because the spontaneous mutation rate to resistance (2x10-8) if much lower than the number of cells being tested from each lineage (5x106) it is very unlikely that these mutants arose on the selective media. Instead, the most reasonable conclusion is that the resistant mutants arose spontaneously and randomly during the growth of lineages in the absence of drug and were enriched because they out-competed the parent population. Three random drug-resistant mutants were chosen from independent lineages and tested by DNA sequencing for the presence of mutations in gyrA and B, in parC and E, and in marR and acrR. In each case the mutations originally present in LM695 were confirmed and in addition each of the mutants was found to have acquired a new mutation in parC (S80R in two cases, and E84K in one case). The MIC CIP of each of the mutants had increased from 0.75 to >32 microg/mL, and the exponential doubling time in rich medium had increased significantly, by approximately10% per generation (Table 3). Thus, the selection of a spontaneous parC mutation in LM695 decreased its susceptibility to ciprofloxacin and increased its growth rate. From these experiments we concluded that the phenotypes generated directly by strain construction (LM695-->LM707; reduced drug susceptibility and increased growth fitness) could also be generated by a variety of spontaneous mutations, and that the growth advantage phenotype could be enriched by growth selection in the absence of drug.
###end p 38
###begin title 39
Selection of LM695 to faster growth and increased MIC.
###end title 39
###begin p 40
Dt; doubling time in min in LB medium at 37degreesC.
###end p 40
###begin p 41
P-value; Significance of the difference in generation time relative to LM695, the parental strain, Students t-test for independent samples, n = 10 for each strain.
###end p 41
###begin p 42
Mutation; Identity of the new mutation identified in each evolved strain.
###end p 42
###begin p 43
MIC; for ciprofloxacin (microg/ml) of LM695 and each of the evolved strains.
###end p 43
###begin title 44
Discussion
###end title 44
###begin p 45
###xml 21 28 21 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E. coli</italic>
###xml 778 781 778 781 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000541-Andersson1">[6]</xref>
###xml 782 785 782 785 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000541-Andersson2">[7]</xref>
###xml 855 862 855 862 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="ppat-1000541-t001">Table 1</xref>
###xml 868 876 868 876 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000541-g001">Figure 1</xref>
###xml 1416 1420 1416 1420 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000541-Borman1">[21]</xref>
###xml 21 28 <span type="species:ncbi:562">E. coli</span>
###xml 1377 1380 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
A set of 28 isogenic E. coli strains was constructed and used to measure the relationship between the accumulation of fluoroquinolone resistance mutations, drug susceptibility, and growth fitness. The question was whether the accumulation of up to five resistance mutations, commonly found in resistant clinical isolates, would progressively reduce bacterial fitness. Most of the published data on the relationship between drug resistance and bacterial fitness would predict two possibilities: (i) that these mutations would cause little or no fitness cost, explaining their high frequency among resistant isolates; or (ii) that their accumulation would cause a progressive decrease in bacterial fitness, and require additional fitness-compensating mutations to restore fitness [6],[7]. The data from this study support, in part, each of these scenarios (Table 1, and Figure 1). However, they also revealed, for some combinations of resistance mutations, a positive relationship between reduced drug-susceptibility and increased bacterial fitness. This positive relationship could be another driving force in the development of increased resistance to these antibacterial drugs. Although this may be the first demonstration in bacteria that in the absence of an antimicrobial, selection can increase resistance to that antimicrobial, a similar phenomenon has been reported for HIV resistance to a protease inhibitor [21]. Thus, the phenomenon described here may have a broad biological significance.
###end p 45
###begin p 46
The main conclusions from the data set were the following:
###end p 46
###begin p 47
###xml 448 452 448 452 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">marR</italic>
Some resistance mutations, individually or when incorporated in an already mutant strain, reduced drug susceptibility without significantly reducing fitness. Other mutations were individually or in combination associated with significant fitness costs. This suggests that selection for low-cost mutations, and/or compensating mutations could be selective forces determining the frequency of particular mutations individually or in combination. The marR mutation had the largest negative effect on fitness.
###end p 47
###begin p 48
###xml 143 146 143 146 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">and</underline>
###xml 143 146 143 146 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><underline>and</underline></bold>
###xml 180 188 180 188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000541-g003">Figure 3</xref>
###xml 247 254 247 254 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
In some cases, the addition of a resistance mutation to an already low-fitness mutant strain caused a further reduction in drug susceptibility and an increase in relative fitness (Figure 3). The improved fitness of these strains was also measured in vivo. Thus, particular combinations of resistance mutations could potentially be selected either because they reduce drug susceptibility, and/or because they improve the relative fitness of the mutant strain.
###end p 48
###begin p 49
###xml 133 137 133 137 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">gyrA</italic>
###xml 257 261 257 261 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">marR</italic>
The positive effect of these combinations of resistance mutations on fitness was accompanied by a significant change in the level of gyrA expression measured in a reporter gene assay of supercoiling. This suggests that reversing the negative effects of the marR mutation on gene regulation may be a mechanism for expression of the phenotype.
###end p 49
###begin p 50
Growth of a low-fitness strain in the absence of drug selected for mutants with increased growth fitness and reduced drug susceptibility. Because each culture was initiated with a pure clone, these mutants must have arisen spontaneously during the growth of the cultures and been selected because they had a competitive advantage. This showed that the phenotype could be selected in the absence of drug, and that it was not limited to a unique combination of mutations.
###end p 50
###begin title 51
A general model illustrating evolutionary paths for a lineage under antibiotic selection.
###end title 51
###begin p 52
Mutual compensation, the acquisition of a mutation that simultaneously improves fitness and reduces susceptibility to the antibiotic, is the pathway presented in this manuscript.
###end p 52
###begin p 53
###xml 36 40 36 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">parC</italic>
###xml 45 49 45 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">gyrA</italic>
###xml 118 122 118 122 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">marR</italic>
###xml 311 315 311 315 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000541-Bremer1">[22]</xref>
###xml 402 406 402 406 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000541-Grkovic1">[17]</xref>
###xml 484 488 480 484 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">marR</italic>
###xml 490 497 486 493 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="ppat-1000541-t001">Table 1</xref>
###xml 854 858 850 854 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000541-Nollmann1">[23]</xref>
###xml 859 863 855 859 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000541-Deibler1">[24]</xref>
Molecular details of how particular parC and gyrA mutations together improve the fitness of a resistant strain with a marR mutation are beyond the scope of this study but we can suggest the outlines of a model. Growth rate depends on the rate of transcription regulated in accordance with physiological demands [22]. The MarR protein regulates, directly and indirectly, the transcription of many genes [17] and it is probable that the severe reduction in fitness associated with DeltamarR (Table 1) is because it causes inappropriate patterns of transcription regulation. We suggest that specific mutant forms of DNA gyrase and topoisomerase IV, possibly by acting in concert to influence the level of superhelicity in DNA, restore appropriate levels of gene expression at some loci where the loss of MarR regulation has a negative impact on growth rate [23],[24].
###end p 53
###begin p 54
###xml 15 19 15 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">gyrA</italic>
###xml 24 28 24 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">parC</italic>
###xml 172 179 172 179 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E. coli</italic>
###xml 179 182 179 182 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000541-KompLindgren1">[4]</xref>
###xml 240 244 240 244 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">gyrA</italic>
###xml 290 294 290 294 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">gyrA</italic>
###xml 321 325 321 325 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">parC</italic>
###xml 378 382 378 382 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">gyrA</italic>
###xml 395 399 395 399 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">parC</italic>
###xml 505 509 505 509 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">gyrA</italic>
###xml 532 536 532 536 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">parC</italic>
###xml 804 808 804 808 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">acrR</italic>
###xml 816 821 816 821 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">marOR</italic>
###xml 821 824 821 824 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000541-KompLindgren1">[4]</xref>
###xml 172 179 <span type="species:ncbi:562">E. coli</span>
The particular gyrA and parC resistance mutations studied here are clinically relevant, being among the most common found in fluoroquinolone-resistant clinical isolates of E. coli[4]. Among 30 resistant UTI isolates analyzed: 30/30 had the gyrA S83L mutation; 18/30 had the double mutation gyrA S83L, D87N; 22/30 had the parC mutation S80I; and 15/30 had the triple combination gyrA S83L, D87N, parC S80I (23/30 had some form of triple mutation combination including other substitutions at position 87 of gyrA and/or position 80 of parC). Thus, the combination of target mutations studied here is typical of resistant clinical isolates. As measured by organic solvent tolerance, drug efflux was phenotypically up-regulated in 15/30 of these resistant isolates, associated in most cases with mutations in acrR and/or marOR[4]. The observed frequency of the efflux phenotype is very low relative to the frequency of specific gyrase and topoisomerase mutations in the same isolates, and given the much higher expected probability of mutations that knock out the function of efflux regulator genes it suggests selection against such mutations. This under-representation is consistent with our finding that mutations up-regulating efflux pumps carry significant fitness costs. The growth fitness of clinical isolates cannot be meaningfully compared with the data presented in this paper, in part because clinical isolates are not isogenic, and in part because clinical isolates will already have evolved to ameliorate the fitness costs, if any, associated with their resistance determinants. We believe that our data provide an insight into the likely initial effects on relative fitness and drug susceptibility of different pathways of resistance development. In particular, that one consequence of a following a high-probability but low-fitness evolutionary pathway may be that one or more steps may be driven by selection for increased fitness in the absence of drug exposure.
###end p 54
###begin p 55
###xml 125 129 125 129 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000541-Weinreich1">[25]</xref>
###xml 583 591 583 591 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000541-g003">Figure 3</xref>
###xml 707 711 707 711 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000541-Kahlmeter1">[26]</xref>
###xml 712 716 712 716 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000541-Kahlmeter2">[27]</xref>
###xml 1200 1207 1200 1207 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="ppat-1000541-t002">Table 2</xref>
###xml 1361 1365 1361 1365 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000541-Zhao1">[28]</xref>
How fluoroquinolone resistance evolves in nature will depend on the genotype being selected and on the selective environment [25] but it is likely include mutational steps that reduce bacterial fitness. Bacteria that progress down an evolutionary path with reduced fitness relative to a competing population may be driven to extinction, or may, given the opportunity by mutation, acquire a change that increases their relative fitness thus improving their chances of survival. Evolutionary paths that could be taken on the road to extinction or antibiotic resistance are outlined in Figure 3. The low-fitness mutants LM695 and LM882 each have MICs that lie under the resistance breakpoint for ciprofloxacin [26],[27]. Such mutants are at a critical stage in resistance development: having low fitness they may be driven to extinction by natural selection; being under the resistance breakpoint they may avoid detection in a clinical setting; however, they are, as shown here, only one mutational step away from a high-level resistance phenotype with increased fitness, without additional exposure to the drug. The magnitude of these co-selected changes in fitness and susceptibility are significant (Table 2). These data argue in favor of testing anti-mutant dosing strategies, or other measures that could prevent the enrichment of low-level resistant mutants [28].
###end p 55
###begin title 56
Materials and Methods
###end title 56
###begin title 57
Strains and growth conditions
###end title 57
###begin p 58
###xml 86 89 86 89 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000541-KompLindgren1">[4]</xref>
###xml 91 98 91 98 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E. coli</italic>
###xml 167 174 167 174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="ppat-1000541-t001">Table 1</xref>
###xml 91 98 <span type="species:ncbi:562">E. coli</span>
C1186 is a multiply mutant fluoroquinolone resistant UTI isolate previously described [4]. E. coli K12 MG1655 wild-type was the starting strain for all constructions (Table 1). Liquid growth medium was Luria broth (LB) while solid medium was Luria-Bertani agar (LA). Strains were grown at 37degreesC. Ciprofloxacin (Bayer HealthCare AG, Wuppertal, Germany) was dissolved in 0.1 M NaOH at 100 microg/mL then further diluted in LA in selective plates.
###end p 58
###begin title 59
MIC determinations
###end title 59
###begin p 60
###xml 164 167 158 161 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000541-KompLindgren1">[4]</xref>
MIC was determined by Etest (AB BIODISK, Solna, Sweden) on Mueller-Hinton agar plates incubated for 16 to 18 h at 37degreesC with quality control reference strains [4] as recommended by the Clinical and Laboratory Standards Institute ().
###end p 60
###begin title 61
Selection of mutations and strain construction
###end title 61
###begin p 62
###xml 36 40 36 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">gyrA</italic>
###xml 45 49 45 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">parC</italic>
###xml 80 87 80 87 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E. coli</italic>
###xml 324 328 324 328 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">marR</italic>
###xml 330 334 330 334 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">acrR</italic>
###xml 336 340 336 340 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">yfaH</italic>
###xml 342 346 342 346 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">metC</italic>
###xml 351 355 351 355 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">araB</italic>
###xml 395 399 390 394 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000541-Yu1">[29]</xref>
###xml 415 416 410 411 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 420 421 415 416 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 507 508 502 503 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">R</sup>
###xml 518 522 513 517 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000541-Cherepanov1">[30]</xref>
###xml 764 772 735 743 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="ppat.1000541.s001">Table S1</xref>
###xml 80 87 <span type="species:ncbi:562">E. coli</span>
Spontaneous resistance mutations in gyrA and parC were selected sequentially in E. coli MG1655 in LB with ciprofloxacin at 2-8-fold MIC and mutations were identified by DNA sequencing. Individual mutations were always moved into a clean genetic background (MG1655) after initial selection. Deletion-replacement mutations in marR, acrR, yfaH, metC and araB were made by lambda-red recombineering [29] in NC397 (a Lac+ Nad+ derivative of DY329) using PCR amplified linear DNA from pCP16 with an FRT-bounded TcR cassette [30]. The PCR reaction protocol was 95degreesC 5 min followed by 30 cycles of 95degreesC 15 sec, 55degreesC 20 sec, 72degreesC 240 sec. PCR primer sequences with details of the deletion-replacement boundaries are shown in Supporting Information (Table S1).
###end p 62
###begin title 63
Construction of isogenic strains
###end title 63
###begin p 64
###xml 137 141 137 141 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">marR</italic>
###xml 146 150 146 150 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">acrR</italic>
###xml 204 208 204 208 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">gyrA</italic>
###xml 213 217 213 217 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">parC</italic>
###xml 271 275 271 275 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">yfaH</italic>
###xml 284 285 284 285 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">R</sup>
###xml 295 299 295 299 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">metC</italic>
###xml 308 309 308 309 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">R</sup>
###xml 345 349 333 337 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">gyrA</italic>
###xml 354 358 342 346 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">parC</italic>
###xml 523 524 506 507 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">R</sup>
###xml 616 620 599 603 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000541-Cherepanov1">[30]</xref>
###xml 51 59 <span type="species:ncbi:10678">phage P1</span>
Isogenic derivatives of MG1655 were constructed by phage P1-mediated transduction. Transduction of the deletion-replacement mutations in marR and acrR was selected directly on LA+Tc. When transducing the gyrA and parC mutations selection was made for the linked markers, yfaH<>Frt::TcR::Frt and metC<>Frt::TcR::Frt, each approximately10 kb from gyrA and parC, respectively. Note that we are using the symbol <> to indicate a replacement generated by lambda red homologous recombination technology. After transduction the TcR marker was removed by Flp-catalyzed excision expressed following transformation with pCP20 [30]. All strain constructs were confirmed by DNA sequencing.
###end p 64
###begin title 65
Growth competition assays
###end title 65
###begin p 66
###xml 12 16 8 12 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">araB</italic>
###xml 226 230 218 222 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">araB</italic>
###xml 389 396 379 386 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="ppat-1000541-t001">Table 1</xref>
###xml 512 514 496 498 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;3</sup>
###xml 637 639 621 623 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;3</sup>
###xml 730 737 714 721 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="ppat-1000541-t001">Table 1</xref>
###xml 1082 1085 1060 1063 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ara</italic>
###xml 1085 1086 1063 1064 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1104 1108 1078 1082 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">araB</italic>
###xml 1299 1300 1273 1274 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S</italic>
###xml 1339 1343 1313 1317 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000541-Dean1">[31]</xref>
###xml 1427 1428 1401 1402 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S</italic>
LM347 (DeltaaraB<>FRT) was used as the standard wild type strain in growth competitions against which each of the constructed mutant strains was competed. This strain was tested against its parent MG1655 showing that the DeltaaraB mutation was neutral (relative growth rate 1.002+/-0.005). To support statistical analysis each competition was tested in at least 5 independent experiments (Table 1). To initiate growth competitions, each strain was grown in LB at 37degreesC 12 h, mixed in a 1:1 ratio, diluted 10-3 into LB, then grown 23 h to complete a growth cycle. Each successive growth cycle was initiated by diluting the mixture 10-3 into LB. Each competition experiment (4 cycles) was made the number of times indicated in Table 1. For some low-fitness strains such as LM595 the mutant population became too low to detect after the second or third cycle of competition. After the initial mixing, and after each growth cycle, appropriate dilutions of the mixture were plated onto MacConkey agar plates containing 1% arabinose. Plates were incubated 37degreesC overnight. Red (ara+) and white (DeltaaraB) colonies were scored. The change in the ratio of mutant/wild-type was used to estimate the selection coefficient per generation of each of the constructed strains according to the formula: S = ln2 (mutant/wild-type) / generation [31]. Relative fitness per generation with respect to the wild-type LM347 is defined as S+1. Note that the fitness defects could be due to defects at any stage of the growth cycle (lag, exponential, stationary phase).
###end p 66
###begin title 67
###xml 47 51 <span type="species:ncbi:10090">mice</span>
The ascending urinary tract infection model in mice
###end title 67
###begin p 68
###xml 27 34 27 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 99 103 99 103 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000541-Hvidberg1">[16]</xref>
###xml 174 181 174 181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="ppat.1000541.s002">Text S1</xref>
###xml 124 129 <span type="species:ncbi:10090">mouse</span>
###xml 336 340 <span type="species:ncbi:10090">mice</span>
Relative bacterial fitness in vivo was measured using an established urinary tract infection model [16]. Details, including mouse strain and ethical permission, are given in Text S1. Competitive index was calculated as the geometric mean of the ratio of mutant/wild-type bacteria isolated from each organ (urine, bladder, kidneys) of 8 mice per experiment, normalised to the ratio at the time of inoculation.
###end p 68
###begin title 69
Growth rate measurements
###end title 69
###begin p 70
###xml 101 104 101 104 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">600</sub>
Exponential doubling times were calculated by measuring the increase in optical density at 600 nm (OD600) at 10-min intervals, using a BioscreenC machine (Oy Growth Curves Ab Ltd. Helsinki, Finland).
###end p 70
###begin title 71
Evolution of improved fitness mutants
###end title 71
###begin p 72
###xml 86 88 82 84 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;8</sup>
###xml 227 228 201 202 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">9</sup>
The mutation rate of LM695 to resistance on LA+3 microg/mL ciprofloxacin (CIP) is 2x10-8 measured by fluctuation test. Independent lineages were inoculated in 96x200 microL wells, and grown 24 h at 37degreesC to approximately109 CFU/mL. 2 microL was transferred to initiate a new growth cycle. 5 microL was plated on LA+3 microg/mL CIP to assay for resistant mutants.
###end p 72
###begin title 73
Supercoiling assay
###end title 73
###begin p 74
###xml 107 111 107 111 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000541-Bagel1">[19]</xref>
###xml 213 221 213 221 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">topA-luc</italic>
###xml 229 237 229 237 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">gyrA-luc</italic>
###xml 239 243 239 243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000541-Preisler1">[20]</xref>
###xml 266 273 266 273 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="ppat.1000541.s003">Text S2</xref>
The relative supercoiling degree was determined using a published assay. The quotient of supercoiling, Qsc [19] is defined as the ratio of luciferase activity from two different supercoiling sensitive promoters, ptopA-luc, and, pgyrA-luc, [20]. Details are given in Text S2.
###end p 74
###begin title 75
Supporting Information
###end title 75
###begin p 76
Oligonucleotides used to amplify linear PCR fragments for lambda-red recombineering
###end p 76
###begin p 77
(0.03 MB DOC)
###end p 77
###begin p 78
Click here for additional data file.
###end p 78
###begin p 79
###xml 47 51 <span type="species:ncbi:10090">mice</span>
The ascending urinary tract infection model in mice.
###end p 79
###begin p 80
(0.03 MB DOC)
###end p 80
###begin p 81
Click here for additional data file.
###end p 81
###begin p 82
Supercoiling assay.
###end p 82
###begin p 83
(0.03 MB DOC)
###end p 83
###begin p 84
Click here for additional data file.
###end p 84
###begin p 85
###xml 48 53 <span type="species:ncbi:10090">mouse</span>
We thank Jytte Mark Andersen for performing the mouse model experiments.
###end p 85
###begin title 86
References
###end title 86
###begin article-title 87
The quinolones: past, present, and future.
###end article-title 87
###begin article-title 88
Mechanisms of action of antimicrobials: focus on fluoroquinolones.
###end article-title 88
###begin article-title 89
###xml 61 77 <span type="species:ncbi:562">Escherichia coli</span>
###xml 92 100 <span type="species:ncbi:9606">patients</span>
Mutation rate and evolution of fluoroquinolone resistance in Escherichia coli isolates from patients with urinary tract infections.
###end article-title 89
###begin article-title 90
###xml 75 91 <span type="species:ncbi:562">Escherichia coli</span>
Biological cost of single and multiple norfloxacin resistance mutations in Escherichia coli implicated in urinary tract infections.
###end article-title 90
###begin article-title 91
Effects of antibiotic resistance on bacterial fitness, virulence, and transmission.
###end article-title 91
###begin article-title 92
The biological cost of mutational antibiotic resistance: any practical conclusions?
###end article-title 92
###begin article-title 93
Chloramphenicol resistance in vancomycin-resistant enterococcal bacteremia: impact of prior fluoroquinolone use?
###end article-title 93
###begin article-title 94
European Surveillance of Antimicrobial Consumption (ESAC): outpatient quinolone use in Europe.
###end article-title 94
###begin article-title 95
###xml 47 71 <span type="species:ncbi:1313">Streptococcus pneumoniae</span>
Fitness costs of fluoroquinolone resistance in Streptococcus pneumoniae.
###end article-title 95
###begin article-title 96
###xml 49 75 <span type="species:ncbi:1773">Mycobacterium tuberculosis</span>
The competitive cost of antibiotic resistance in Mycobacterium tuberculosis.
###end article-title 96
###begin article-title 97
###xml 53 74 <span type="species:ncbi:1280">Staphylococcus aureus</span>
Molecular genetic and structural modeling studies of Staphylococcus aureus RNA polymerase and the fitness of rifampin resistance genotypes in relation to clinical prevalence.
###end article-title 97
###begin article-title 98
The units of selection and measures of fitness.
###end article-title 98
###begin article-title 99
###xml 61 66 <span type="species:ncbi:10090">mouse</span>
Development of a long-term ascending urinary tract infection mouse model for antibiotic treatment studies.
###end article-title 99
###begin article-title 100
Regulation of bacterial drug export systems.
###end article-title 100
###begin article-title 101
Analysis of DNA supercoiling induced by DNA-protein interactions.
###end article-title 101
###begin article-title 102
###xml 101 117 <span type="species:ncbi:562">Escherichia coli</span>
Impact of gyrA and parC mutations on quinolone resistance, doubling time, and supercoiling degree of Escherichia coli.
###end article-title 102
###begin article-title 103
Role of novel gyrA mutations in the suppression of the fluoroquinolone resistance genotype of vaccine strain Salmonella Typhimurium vacT (gyrA D87G).
###end article-title 103
###begin article-title 104
###xml 14 49 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Resistance of human immunodeficiency virus type 1 to protease inhibitors: selection of resistance mutations in the presence and absence of the drug.
###end article-title 104
###begin article-title 105
Modulation of chemical composition and other parameters of the cell by growth rate.
###end article-title 105
###begin article-title 106
###xml 16 32 <span type="species:ncbi:562">Escherichia coli</span>
Thirty years of Escherichia coli DNA gyrase: From in vivo function to single-molecule mechanism.
###end article-title 106
###begin article-title 107
###xml 40 47 <span type="species:ncbi:562">E. coli</span>
Topoisomerase IV, alone, unknots DNA in E. coli.
###end article-title 107
###begin article-title 108
Darwinian evolution can follow only very few mutational paths to fitter proteins.
###end article-title 108
###begin article-title 109
European Committee on Antimicrobial Susceptibility Testing (EUCAST) Technical Notes on antimicrobial susceptibility testing.
###end article-title 109
###begin article-title 110
European harmonization of MIC breakpoints for antimicrobial susceptibility testing of bacteria.
###end article-title 110
###begin article-title 111
A unified anti-mutant dosing strategy.
###end article-title 111
###begin article-title 112
###xml 64 80 <span type="species:ncbi:562">Escherichia coli</span>
An efficient recombination system for chromosome engineering in Escherichia coli.
###end article-title 112
###begin article-title 113
###xml 19 35 <span type="species:ncbi:562">Escherichia coli</span>
Gene disruption in Escherichia coli: TcR and KmR cassettes with the option of Flp-catalyzed excision of the antibiotic-resistance determinant.
###end article-title 113
###begin article-title 114
###xml 72 88 <span type="species:ncbi:562">Escherichia coli</span>
Fitness effects of amino acid replacements in the beta-galactosidase of Escherichia coli.
###end article-title 114
###begin p 115
The authors have declared that no competing interests exist.
###end p 115
###begin p 116
This work was supported by grants from the Swedish Research Council (Vetenskapsradet , project K2008-58X-20686-01-3 and project 621-2005-3902) to DH and the EU 6th Framework Programme (EAR project) to DH and NFM. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 116

